BRIDGEWATER, N.J., April 20, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that it will release its first quarter
2020 financial results on Thursday, April
30, 2020.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Thursday, April
30, 2020 to discuss the financial results and provide a
business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 317-6003 (domestic) or (412)
317-6061 (international) and referencing conference ID number
2121512. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through May
14, 2020 by dialing (877) 344-7529 (domestic) or (412)
317-0088 (international) and referencing replay access code
10142785. A webcast of the call will also be archived for 90 days
under the Investor Relations section of the company's website at
www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product, ARIKAYCE®
(amikacin liposome inhalation suspension), is the first and only
therapy approved in the United States for the treatment
of refractory Mycobacterium avium complex (MAC)
lung disease as part of a combination antibacterial drug regimen
for adult patients with limited or no alternative treatment
options. MAC lung disease is a chronic, debilitating condition that
can cause severe and permanent lung damage. Insmed's earlier-stage
clinical pipeline includes INS1007, a novel oral reversible
inhibitor of dipeptidyl peptidase 1 with therapeutic potential in
non-cystic fibrosis bronchiectasis and other inflammatory diseases,
and INS1009, an inhaled formulation of a treprostinil prodrug that
may offer a differentiated product profile for rare pulmonary
disorders, including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-first-quarter-2020-financial-results-conference-call-on-thursday-april-30-2020-301042223.html
SOURCE Insmed Incorporated